Designing Programmable Peptide Nucleic Acid-based Nanovaccines for Anticancer Immune Activation.

ABSTRACT: Targeted delivery of antigens and adjuvants to the immune cells without eliciting uncontrolled inflammation is a major challenge in cancer vaccine development. Here, a highly versatile and programmable peptide nucleic acid (PNA)-based vaccine nanoplatform (PVN) is reported to elicit a robust anti-tumor immune response against B16-OVA syngeneic melanoma model. The PVN is built on an 11-mer PNA scaffold, enabling efficient "one-pot" loading of a PNA-modified ovalbumin antigenic peptide (SIINFEKL), CpG adjuvant, and a PNA-derivatized LLP2A ligand (an immune cell and melanoma cell targeting ligand). Super-resolution fluorescence imaging reveals the spatial arrangement of OVA₈ within LP_10-12[OVA₈/CpG/LLP2A], while circular dichroism spectroscopy confirmsparallel

SUBMITTER: Huang Y 

PROVIDER: S-EPMC12723328 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature